Clinical trials: Human Challenge Trial
Healthy
First-in-Human Trial of Single Ascending Dose, Multiple Ascending Dose and Malaria Challenge Model in Healthy Participants
The primary purpose of this study was to investigate the safety and tolerability of M5717 and to characterize the Pharmacokinetics (PK) /Pharmacodynamic relationship between M5717 PK and parasite clearance in healthy participants…
- Trial name
- NCT03261401
- Testing
- M5717
- Where
- Australia
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Merck KGaA, Darmstadt, Germany
Celiac Disease
VTP-1000 in Adults With Celiac Disease
GLU001 is a first-in-human clinical trial to assess the safety and tolerability of VTP-1000 for adults with celiac disease. This trial will assess VTP-1000 at various dose levels compared to placebo in a single ascending dose…
- Trial name
- NCT06310291
- Testing
- VTP-1000
- Where
- 16 sites in United States
- Volunteers
- 45 people
- Sponsor
- Barinthus Biotherapeutics
Allergic Rhinitis
OC000459 Dose Finding Study in Hay Fever Sufferers.
The primary objective of this study is to evaluate a range of dose levels for efficacy in the control of symptoms of allergic rhinitis
- Trial name
- NCT00697281
- Testing
- OC000459
- Where
- Austria
- Volunteers
- 120 people
- Sponsor
- Oxagen Ltd
COPD Exacerbation Acute, COPD With Acute Lower Respiratory Infection
RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection
Vapendavir (VPV) is a drug being developed to treat human rhinovirus (RV) infection, one virus responsible for the common cold. Vapendavir prevents the virus from entering cells and making more infectious copies of itself.
- Conditions
- COPD Exacerbation Acute, COPD With Acute Lower Respiratory Infection, Rhinovirus, Virus Diseases
- Trial name
- NCT06149494
- Testing
- Vapendavir
- Where
- United Kingdom
- Volunteers
- 52 people
- Sponsor
- Altesa Biosciences, Inc.
Malaria (Plasmodium Falciparum)
Challenge Trial of PfSPZ-LARC2 Vaccine in Burkina Faso
This is a randomized, double-blind, placebo-controlled, Phase 1 trial of Plasmodium falciparum (Pf) late liver stage-arresting replication-competent (LARC) sporozoite (SPZ) malaria vaccine (Sanaria® PfSPZ-LARC2 Vaccine)…
- Trial name
- BFSPZL3 (NCT07730177)
- Testing
- PfSPZ-LARC2 Vaccine, PfSPZ Challenge, Normal Saline
- Where
- Burkina Faso
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Healthy Adult Participants, Asthma Exacerbation
RIG 101 Trial in Healthy Adults and Adults With Asthma
Nested Phase 1-2 Trial of RIG-101 in Healthy and Asthmatic Participants Assessing Safety, Tolerability and Viral Challenge Efficacy
- Conditions
- Healthy Adult Participants, Asthma Exacerbation, Safety and Efficacy
- Trial name
- NCT07488897
- Testing
- RIG-101
- Where
- 2 sites in United Kingdom
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- RIGImmune Inc.
Malaria
PfSPZ Vaccine: Dose Optimization With Heterologous Challenge in Healthy Malaria-Naïve Adults
This is an open-label evaluation of the safety, tolerability, immunogenicity and efficacy of PfSPZ Vaccine administered by direct venous inoculation (DVI) in healthy, malaria-naïve adult subjects.
- Trial name
- NCT02601716
- Testing
- PfSPZ Vaccine, CHMI (7G8), CHMI (NF135.C10)
- Where
- 2 sites in United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Healthy
A Study of JNJ-64281802 Against Dengue Serotype 1 Infection in a Dengue Human Challenge Model in Healthy Adult Participants
The purpose of this study is to assess the antiviral activity of JNJ-64281802 versus placebo in terms of reduction of dengue virus 1 (DENV-1) ribonucleic acid (RNA) viral load (VL).
- Trial name
- NCT04480736
- Testing
- JNJ-64281802 High dose, JNJ-64281802 Medium dose, JNJ-64281802 Low dose
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Malaria, Plasmodium Falciparum Malaria
Dose Escalation, Randomized Controlled Trial to Evaluate the Safety, Immunogenicity and Efficacy of Intravenously Administered Attenuated Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in Tanzanian Adults
This trial will evaluate whether relatively non-immune populations in endemic countries can effectively generate significant cellular and humoral immune responses that confer protection against P.
- Trial name
- NCT02132299
- Testing
- PfSPZ Vaccine, PfSPZ Challenge
- Where
- Tanzania
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Influenza A H1N1
Dose, Safety, and Pathogenicity of a New Influenza H1N1 Challenge Strain
A total of up to 90 participants may be given H1N1 influenza challenge virus. In Part A, 40 participants will be randomly allocated to one of two groups to be given one of two virus doses (Virus Dose 1 or Virus Dose 2).
- Trial name
- NCT05572450
- Testing
- Infectious Titre 1, Infectious Titre 2, Infectious Titre 3
- Where
- United Kingdom
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Hvivo
Influenza
Influenza Vaccine Challenge Study in Healthy Subjects
The purpose of this research is to study the safety, tolerability and effectiveness of the investigational influenza vaccine in healthy volunteers infected with an attenuated influenza A virus.
- Trial name
- NCT01226758
- Testing
- Influenza vaccine (FLU-v)
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- PepTcell Limited
Influenza A H3N2
Dose, Safety, and Pathogenicity of a New Influenza A H3N2 Challenge Strain
An Exploratory Study to Establish the Dose, Safety and Pathogenicity of a New Influenza A H3N2 Challenge Strain in Healthy Participants 18 to 55 Years of Age In Part A, up to 40 participants will be randomly allocated to one of…
- Trial name
- NCT06613737
- Testing
- Influenza A H3N2 virus dose arm 1, Influenza A H3N2 virus dose arm 2, Influenza A H3N2 virus dose arm 3
- Where
- United Kingdom
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Hvivo
Malaria
Safety, Tolerability and Immunogenicity of PfSPZ Vaccine in an Age De-escalation Trial in Equatorial Guinea.
This trial will evaluate the safety, tolerability, and immunogenicity of PfSPZ Vaccine in healthy Equatoguinean adults, adolescents, children and infants who receive doses of 0.9x10^6, 1.8x10^6 or 2.7x10^6 PfSPZ Vaccine via…
- Trial name
- NCT02859350
- Testing
- PfSPZ Vaccine, PfSPZ Challenge (for CHMI), Normal Saline
- Where
- Equatorial Guinea
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.